3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma
7
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Recurrence
3
Neoplasms
2
Leukemia, B-Cell
2
Burkitt Lymphoma
2
Neoplasm, Residual
1
Mature B-Cell Malignancies
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Heart Failure
1
Dendritic Cell Sarcoma, Interdigitating
1
Cytokine Release Syndrome
1
Interventions
venetoclax
5
Rituximab
5
Cyclophosphamide
4
Whole-Body Irradiation
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
zanubrutinib
2
pirtobrutinib
2
fludarabine phosphate
2
fludarabine
2
Specimen Handling
2
Prednisone
2
Mycophenolic Acid
2
Lenalidomide
2
CT-P10
2
Biopsy
2
treosulfan
1
pomalidomide
1
obinutuzumab
1
ibrutinib
1
Vincristine
1
Tacrolimus
1
Stem Cell Transplantation
1
Sirolimus
1
R-CHOP protocol
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Methotrexate
1
Melphalan
1
Maintenance
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
obinutuzumab
×
30 days
×
Clear all
NCT05100862
2026-05-27
MAHOGANY
BeOne Medicines
Phase 3
Recruiting
780 enrolled